{"id":"W2948365327","doi":"10.1200/jco.2019.37.18_suppl.lba3","title":"ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Anthracycline; Population; Neutropenia; Dexrazoxane; Doxorubicin; Randomization; Placebo; Phases of clinical research; Urology; Randomized controlled trial; Oncology; Surgery; Gastroenterology; Toxicity; Chemotherapy; Cancer; Breast cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00592749,0.0004544874,0.007254254,0.0004495597,0.0000474478,0.00002028056,0.000319549,0.0006490832,0.000277589],"category_scores_gemma":[0.003397009,0.0002750694,0.001202695,0.0003642425,0.0003608959,0.0002748414,0.0000773576,0.001396704,0.00005439199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004381629,"about_ca_system_score_gemma":0.001872582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007001128,"about_ca_topic_score_gemma":0.000116484,"domain_scores_codex":[0.9912674,0.001219901,0.005358537,0.0005017448,0.001104613,0.0005478],"domain_scores_gemma":[0.9831178,0.01039214,0.004534005,0.0005295649,0.0009218549,0.0005046435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.893706,0.02746017,0.0103572,0.00003823786,0.001878109,0.0006662012,0.0001685492,0.000088702,0.00006438758,0.00009474614,0.0005647083,0.06491303],"study_design_scores_gemma":[0.8906994,0.09628259,0.001965133,0.0003404087,0.001827987,0.00006080647,0.0001509692,0.00008115343,0.0001757444,0.00005433171,0.008139698,0.0002218237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843522,0.001716993,0.00004004654,0.001839374,0.003351632,0.005946347,0.00001132855,0.0000137542,0.002728371],"genre_scores_gemma":[0.9963127,0.0007969318,0.001147182,0.0004908342,0.0007575855,0.0001554281,0.00002505471,0.00004461137,0.0002696337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06882241,"threshold_uncertainty_score":0.9999701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06501265917635984,"score_gpt":0.4374574538321799,"score_spread":0.3724447946558201,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}